key: cord-0777492-528u9wpa authors: Kielt, Matthew J.; Murphy, Angela; Smathers, Jodi; Bates, MaLeah; Nelin, Leif D.; Shepherd, Edward G. title: In‐hospital respiratory viral infections for patients with established BPD in the SARS‐CoV‐2 era date: 2021-10-12 journal: Pediatr Pulmonol DOI: 10.1002/ppul.25714 sha: 41a1837810a6f3d83108afb02e52b53827aa7870 doc_id: 777492 cord_uid: 528u9wpa OBJECTIVE: Our objective was to test the hypothesis that in‐hospital respiratory viral infections (RVI) would be significantly lower in a cohort of patients with established bronchopulmonary dysplasia (BPD) exposed to a severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection prevention protocol when compared to historical controls. STUDY DESIGN: On April 1, 2020, we implemented a universal infection prevention protocol to minimize the risk of nosocomial SARS‐CoV‐2 transmission in a dedicated BPD intensive care unit. We performed a retrospective cohort study and included patients with established BPD, as defined by the 2019 Neonatal Research Network criteria, admitted to our center who underwent real‐time polymerase‐chain‐reaction RVI testing between January 1, 2015 and March 31, 2021. We excluded patients readmitted from home. We compared the proportion of positive tests to the number of tests performed and the distribution of viral respiratory pathogens in the pre‐ and post‐SARS‐CoV‐2 eras. RESULTS: Among 176 patients included in the study, 663 RVI tests were performed and 172 (26%) tests were positive. The median number of tests performed, measured in tests per patient per month, in the SARS‐CoV‐2 era was not significantly different compared to the pre‐SARS‐CoV‐2 era (0.45 vs. 0.34 tests per patient per month, p = .07). The proportion of positive RVI tests was significantly lower in the SARS‐CoV‐2 era when compared to the pre‐SARS‐CoV‐2 era (0.06 vs. 0.30, p < .0001). No patients tested positive for SARS‐CoV‐2 in the SARS‐CoV‐2 era. CONCLUSIONS: Infection prevention measures developed in response to the SARS‐CoV‐2 pandemic may reduce the risk of RVIs in hospitalized patients with established BPD. Bronchopulmonary dysplasia (BPD) is the most common morbidity of preterm birth and results in lifelong respiratory insufficiency. 1 Despite preventative efforts, the incidence of BPD is increasing due to the increased survival of extremely preterm infants. 2 Exposure to respiratory viral infections (RVI) is an important contributor to respiratory morbidity in early childhood in preterm infants, 3 and in particular former preterm infants with established BPD. 4, 5 Among patients with BPD, RVIs may first occur in the neonatal intensive care unit (NICU) [6] [7] [8] and are associated with increased length of stay, severe disease course, unnecessary exposure to antibiotics, nosocomial viral outbreaks in the NICU, and death. 7 Though nosocomial RVIs in the NICU are relatively infrequent, multiple reports suggest that viral transmission to infants may occur in the setting of routine interactions with medical staff, families, and visitors. 3, [8] [9] [10] In response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, NICUs have adopted policies to prevent the nosocomial transmission of SARS-CoV-2 to vulnerable preterm infants, including those with established BPD. 11, 12 Outside of the NICU, public health measures including social distancing and mask use have been thought to reduce the transmission not only of SARS-CoV-2 but of RVIs of any type. 13, 14 It is, therefore, plausible that NICU infection prevention policies designed to prevent the transmission of SARS-CoV-2 are associated with reduced transmission of RVIs of any type to patients with established BPD in the NICU, but this has not been studied. The objective of this study was therefore to test the hypothesis that in-hospital RVIs would be significantly lower in a cohort of patients with established BPD admitted during the global pandemic who were exposed to a SARS-CoV-2 infection prevention protocol when compared to historical controls admitted before the global pandemic. This retrospective cohort study was performed in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) reporting guidelines, which were developed to provide guidance in how to report observational research. 15 Our study population included infants admitted to our center with an established diagnosis of BPD, as defined by 2019 Neonatal Research Network (NRN) criteria. 16 The 2019 NRN criteria stratify patients into BPD grades at 36 weeks post-menstrual age (PMA) where grade 1 corresponds to patients requiring nasal cannula ≤2 L/min (lpm), grade 2 corresponds to patients requiring noninvasive positive airway pressure (includes nasal cannula >2 lpm, nasal continuous positive airway pressure [nCPAP] , and noninvasive positive pressure ventilation), and grade 3 corresponds to patients requiring invasive mechanical ventilation. 16 We included patients with BPD who underwent clinical RVI testing between January 1, 2016, and March 31, 2021. We excluded patients born ≥32 weeks gestation and patients re-admitted from home. A formal sample size was not determined as the cohort included all patients who met the criteria in the study period. RVI testing data were abstracted from the electronic health record. RVI diagnostic data were then joined to clinical data in a prospectively maintained database. Abstracted clinical data included maternal and infant demographics, perinatal exposures including prenatal steroids and chorioamnionitis, postnatal exposures including intubation in the delivery room, and respiratory support data at 36 weeks PMA. The Nationwide Children's Hospital (NCH) institutional review board approved this study with a waiver of consent. We performed this study in the BPD unit at NCH, a 24-bed ward dedicated to the care of infants with established BPD. 16 The BPD unit is in a different building than the level IV NICU and consists of 10 single rooms and 7 double rooms. Single rooms are generally reserved for patients with anticipated prolonged lengths of stay and infants who have a history of colonization with methicillin resistant staphylococcus aureus (MRSA). Our unit policy is to screen for MRSA via nasal swab on all patients admitted from an outside hospital at the time of admission. We do not perform routine MRSA, RVI, or tracheal aspirate surveillance. RVI testing is performed in symptomatic infants if a clinical index of suspicion for RVI is present as detailed below. If a patient develops an RVI in a double room, our policy is to keep both patients in the same room and place both patients on contact and droplet precautions to prevent the spread of infection across the unit. For patients who are RVI positive, precautions are maintained for a total of 28 days but continued longer if a patient remains symptomatic. Our BPD unit has two negative pressure rooms. During the SARS-CoV-2 era, patients would be transferred to a negative pressure room if they were symptomatic and underwent RVI and SARS-CoV-2 testing. Additionally, patients would be transferred to a negative pressure room if there was concern for a potential exposure and the patient was on a level of respiratory support that could generate aerosolized secretions, which included patients on nCPAP and invasive mechanical ventilation. In the prepandemic era, we practiced standard infection control practices (Table 1) . To prevent community transmission of SARS-CoV-2 to patients in our center, on April 1, 2020, we implemented an infection prevention protocol that was part of the overall hospital infection control response to the SARS-CoV-2 pandemic. This protocol (Table 1) To augment our PPE use, we practiced social distancing throughout the unit. Socially distanced rounds were limited to 4 multidisciplinary team members who maintained 6 feet of separation. As our multidisciplinary teams historically consisted of physicians, advanced practice providers, bedside nurses, respiratory therapists, nutritionists, psychologists, social workers, and care coordinators, we developed a rotation schedule in which one multidisciplinary team member would be physically present on rounds each day of the week with the remainder of the team participating virtually using Microsoft Teams (Microsoft Corporation). We transitioned our weekly comprehensive multidisciplinary team meetings, traditionally held in person, to biweekly virtual formats using Microsoft Teams. Hospital policy was revised to encourage staff to monitor for symptoms consistent with viral illness and sick leave policies were revised such that staff would not be required to use sick days if they developed viral symptoms. Lastly, NCH developed a hospital wide policy of limiting family visitation to only one family member at the patient's bedside per 24-h period and only two family members to visit during the entire duration of the patient's hospitalization. For this study, we defined the primary exposure as the "SARS-CoV-2 era," defined as a dichotomous (yes/no) variable between April 1, 2020 (when we implemented the universal infection prevention protocol) and March 21, 2021. Patients undergoing RVI testing before April 1, 2020, defined as the "pre-SARS-CoV-2" group, were categorized as negative exposures while patients who underwent testing after April 1, 2020, defined as the "SARS-CoV-2" group, were categorized as positive exposures. During the study period, patients underwent RVI and SARS-CoV-2 testing if symptomatic and if a clinical index of suspicion for an RVI, including SARS-CoV-2, was present. The diagnosis of RVI is difficult to make in patients with BPD because many of the diagnostic criteria for RVI (i.e., changes in oxygen saturation, changes in sputum production, abnormal radiographic findings) are part of the natural progression of BPD. To encourage consistent RVI testing in our center, we developed clinical practice guidelines that restrict testing to the following criteria: fever without clear source of infection, deterioration in respiratory status that cannot be explained by BPD alone and recent exposure to sick contacts. Though the criteria for RVI testing in the pre-and SARS-CoV-2 eras did not change, asymptomatic patients undergoing routine elective procedures in the later era, such as tracheostomy placement, did undergo SARS-CoV-2 testing before the procedure in accordance with hospital policy. Among infants who underwent RVI testing, bedside nurses col- The primary study outcome was a positive RVI, which we defined as a dichotomous outcome based on the presence or absence of a clinical RT-PCR test detecting one or more viral respiratory pathogens. Disposition, tracheostomy, length of stay (defined as birth to initial NICU discharge in days), supplemental oxygen use at discharge, and gastrostomy placement were reported as secondary outcomes. Maternal Hispanic ethnicity, n (%) 3 (2) 3 (2) 0 (0) .7 American Indian or Alaskan native, n (%) Asian, n (%) 7 (4) 6 (5) 1 (2) Black, n (%) 50 (28) Figure 2B ). In Table 3 , we present the distribution of respiratory viral pathogens identified by clinical testing. During the study period, no patients tested positive for SARS-CoV-2. In the pre-SARS-CoV-2 era, rhino/enterovirus was the most common viral respiratory pathogen identified (135/161, 84%), followed by adenovirus (7/161, 4%), and common coronavirus (5/161, 3%) ( Table 3 ). In the pre-SARS-CoV-2 era, 10 patients had coinfections with multiple viral respiratory pathogens. In the SARS-CoV-2 era, only seven positive rhino/enterovirus RVIs were identified by clinical testing ( Table 3) In-hospital outcomes are presented in Table 4 . Thirteen (7%) of the cohort died and 40 (23%) members of the cohort had tracheostomy placement during the study period ( Table 4 ). The median length of stay in the cohort was 247 days (IQR, 158-361, Table 4 ). Most surviving patients were discharged home on supplmental oxygen (150/158, 95%) and 107/158 surviving discharged members of the cohort received a gastrostomy tube for enteral feedings (Table 4 ). There were no significant differences in adverse in-hospital outcomes observed for cohort members between eras ( Review were conducted during the SARS-CoV-2 pandemic. 21 An important finding of our study is that no SARS-CoV-2 infections were observed in this cohort of patients with established BPD. To our knowledge, this is the first study to report the results of RVI testing in the SARS-CoV-2 era among patients with established BPD during their initial NICU hospitalization. Though SARS-CoV-2 infections have been described in neonates, [22] [23] [24] [25] we know of no reported cases of positive SARS-CoV-2 among patients with established BPD that occurred before initial NICU discharge. In a survey of the Kalyanaraman et al. 27 also reported the case of a former 28 week male with grade 2 BPD who developed severe acute respiratory distress syndrome two weeks following initial NICU discharge. This patient was treated with invasive mechanical ventilation, solumedrol, and hydroxychloroquine in the PICU and discharged home on room air after a 27 day hospital stay. 27 Although the reported incidences of RVIs of any type in the NICU are relatively low, 8, 28, 29 preterm infants with established BPD are highly susceptible to in-hospital RVIs due to their immature immune system 30 and need for prolonged initial NICU hospitalization. 31 Given the underlying pulmonary insufficiency that characterizes lung function in infants with established BPD, 32,33 exposure to RVIs can cause major short-and long-term respiratory morbidities. For example, Taylor et al. 5 showed that among patients with moderate or severe BPD, intercurrent RVIs during the initial NICU hospitalization have negative short-term impacts and are independently associated with an increased odds of oxygen, diuretic, and inhaled corticosteroid use. Of note, we found a marked reduction on the burden of inhospital rhino/enterovirus RVIs (Table 3 ). This is of particular importance for high-risk preterm infants, given the relatively high occurrence of rhino/enterovirus RVIs in this population, which are associated with increased need for respiratory support, nursing care, and medical resources. 3, 8, 18, 19 A recent report by Sánchez García et al. 29 suggested that any symptomatic RVI in the NICU was asso- Community rates for each of these viruses were historically low in Ohio during the study period. 39 The low rates of community transmission of these common RVI pathogens may plausibly explain the observed decrease in RVIs in our study, particularly since none of these pathogens were observed in the SARS-CoV-2 era (Table 3) . Most notably, RSV community transmission in Ohio was surprisingly low during the study period with a 3 week moving average of positive RSV PCR tests ranging from 0% to 0.67% during the study period with little fluctuation observed during the traditional RSV season. 40 Since NREVSS does not track rhino/enterovirus infections, which was the most common RVI pathogen observed in this study and the only RVI pathogen identified during the study period ( We We thank Sarah Wagner and Jan Lie for their assistance in data preparation for this manuscript. We also thank Dr. Chris Gillen and Workshop for their assistance in manuscript preparation. The study was funded by the Ohio Perinatal Research Network at Nationwide Children's Hospital. The authors declare that there are no conflict of interests. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Lung function of adults born at very low birth weight Trends in care practices, morbidity, and mortality of extremely preterm neonates Outcomes of nosocomial viral respiratory infections in high-risk neonates Respiratory syncytial virus infection in children with bronchopulmonary dysplasia Impact of intercurrent respiratory infections on lung health in infants born <29 weeks with bronchopulmonary dysplasia Viral respiratory infections in very low birthweight infants at neonatal intensive care unit: prospective observational study Viral respiratory infections in the neonatal intensive care unit-a review Viral respiratory tract infections in the neonatal intensive care unit: the VIRIoN-I study Hospital-acquired viral respiratory infections in neonates hospitalized since birth in a tertiary neonatal intensive care unit Nosocomial rhinovirus infection in preterm infants Visitation restrictions: is it right and how do we support families in the NICU during COVID-19? Longitudinal survey of COVID-19 burden and related policies in U.S. neonatal intensive care units COVID-19 public health measures and respiratory syncytial virus Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies The diagnosis of bronchopulmonary dysplasia in very preterm infants. an evidence-based approach Nationwide Children's Hospital SARS-CoV-2 Assay EUA Summary Emergency Use Authorization (EUA) Summary. 2020 Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units Respiratory viral infections are not uncommon in neonatal intensive care units Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses Physical interventions to interrupt or reduce the spread of respiratory viruses Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center Nosocomial SARS-CoV-2 transmission in a neonatal unit in Botswana: chronic overcrowding meets a novel pathogen COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres ARDS in an expremature infant with bronchopulmonary dysplasia and COVID-19 Clinical and epidemiologic characteristics of viral infections in a neonatal intensive care unit during a 12-year period Respiratory morbidity associated with viral respiratory infections during neonatal stage in premature infants Postnatal infections and immunology affecting chronic lung disease of prematurity Occurrence and severity of bronchopulmonary dysplasia and respiratory distress syndrome after a preterm birth Infant pulmonary function testing and phenotypes in severe bronchopulmonary dysplasia Long-term impact of bronchopulmonary dysplasia on pulmonary function Seasonal respiratory viral infections. Impact on infants with chronic lung disease following discharge from the neonatal intensive care unit Respiratory syncytial virusassociated acute lower respiratory infections in children with bronchopulmonary dysplasia: systematic review and meta-analysis Rhinovirus infection associated with severe lower respiratory tract illness and worsening lung disease in infants with bronchopulmonary dysplasia An evidence review of face masks against COVID-19 The interseasonal resurgence of respiratory syncytial virus in australian children following the reduction of coronavirus disease 2019-related public health measures CDC-The National Respiratory and Enteric Virus Surveillance System. 2021. Accessed CDC-COVID Data Tracker-Franklin County, OH. 2021 Visitation restrictions: is it right and how do we support families in the NICU during COVID-19? Interdisciplinary care of children with severe bronchopulmonary dysplasia A standardized discharge process decreases length of stay for ventilator-dependent children In-hospital respiratory viral infections for patients with established BPD in the SARS-CoV-2 era